Genesis Therapeutics is a cutting-edge biotech brand that is revolutionizing the field of drug discovery using the power of artificial intelligence (AI). With a team of accomplished drug hunters, deep learning researchers, and software engineers, Genesis Therapeutics is dedicated to developing innovative therapies for patients suffering from severe disorders. Their industry-leading molecular AI platform combines 3D spatial graph modeling and advanced molecular simulation to unlock novel protein targets and explore previously untapped chemical space.

This groundbreaking approach enables them to accelerate the development of critical new medicines. Genesis Therapeutics has recently made waves by announcing a groundbreaking AI discovery deal with Eli Lilly, securing $20 million in upfront cash and potentially reaching a total value of $670 million. This achievement further solidifies their position as a key player in the biotech industry.

With a focus on driving AI in biochemistry, Genesis Therapeutics is at the forefront of innovation, pushing the boundaries of what is possible in drug discovery. For investors and individuals interested in their mission, Genesis Therapeutics offers a wealth of information on their platform and press releases, showcasing their continuous growth and success. To learn more about Genesis Therapeutics and their groundbreaking work, visit their website or get in touch with their dedicated team